NASDAQ:EIGR - Eiger Biopharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $10.80 0.00 (0.00 %) (As of 07/22/2018 10:51 AM ET)Previous Close$10.80Today's Range$10.55 - $10.8552-Week Range$7.46 - $18.00Volume90,586 shsAverage Volume82,454 shsMarket Capitalization$113.83 millionP/E Ratio-2.22Dividend YieldN/ABeta1.82 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates that are in Phase II clinical trial include Lambda, which targets type III IFN receptors; Exendin 9-39 for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California. Receive EIGR News and Ratings via Email Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:EIGR CUSIPN/A Webwww.eigerbio.com Phone650-279-9845 Debt Debt-to-Equity Ratio0.81 Current Ratio4.51 Quick Ratio4.51 Price-To-Earnings Trailing P/E Ratio-2.22 Forward P/E Ratio-3.53 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$2.14 per share Price / Book5.05 Profitability EPS (Most Recent Fiscal Year)($4.86) Net Income$-42,440,000.00 Net MarginsN/A Return on Equity-227.27% Return on Assets-105.48% Miscellaneous Employees16 Outstanding Shares10,540,000Market Cap$113.83 Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions What is Eiger Biopharmaceuticals' stock symbol? Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR." How were Eiger Biopharmaceuticals' earnings last quarter? Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) released its earnings results on Friday, May, 11th. The biotechnology company reported ($0.84) EPS for the quarter, topping analysts' consensus estimates of ($0.96) by $0.12. View Eiger Biopharmaceuticals' Earnings History. What price target have analysts set for EIGR? 7 analysts have issued twelve-month price targets for Eiger Biopharmaceuticals' shares. Their predictions range from $24.00 to $39.00. On average, they expect Eiger Biopharmaceuticals' stock price to reach $30.8571 in the next year. This suggests a possible upside of 185.7% from the stock's current price. View Analyst Ratings for Eiger Biopharmaceuticals. What is the consensus analysts' recommendation for Eiger Biopharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Eiger Biopharmaceuticals' key competitors? Some companies that are related to Eiger Biopharmaceuticals include Vericel (VCEL), PDL BioPharma (PDLI), Scholar Rock (SRRK), Cellular Biomedicine Group (CBMG), Surface Oncology (SURF), Osiris Therapeutics (OSIR), Adverum Biotechnologies (ADVM), NanoString Technologies (NSTG), Neon Therapeutics (NTGN), MeiraGTx (MGTX), Nantkwest (NK), Jounce Therapeutics (JNCE), Allena Pharmaceuticals (ALNA), Agenus (AGEN) and ADMA Biologics (ADMA). Who are Eiger Biopharmaceuticals' key executives? Eiger Biopharmaceuticals' management team includes the folowing people: Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 54)Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Director (Age 55)Mr. James A. Welch, Chief Financial Officer (Age 60)Dr. David Apelian, COO, Exec. Medical Officer & Director (Age 53)Mr. James P. Shaffer, Chief Bus. Officer (Age 51) Has Eiger Biopharmaceuticals been receiving favorable news coverage? Media stories about EIGR stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Eiger Biopharmaceuticals earned a media sentiment score of 0.07 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 47.13 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days. How do I buy shares of Eiger Biopharmaceuticals? Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Eiger Biopharmaceuticals' stock price today? One share of EIGR stock can currently be purchased for approximately $10.80. How big of a company is Eiger Biopharmaceuticals? Eiger Biopharmaceuticals has a market capitalization of $113.83 million. The biotechnology company earns $-42,440,000.00 in net income (profit) each year or ($4.86) on an earnings per share basis. Eiger Biopharmaceuticals employs 16 workers across the globe. How can I contact Eiger Biopharmaceuticals? Eiger Biopharmaceuticals' mailing address is 350 CAMBRIDGE AVE SUITE 350, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-279-9845 or via email at [email protected] MarketBeat Community Rating for Eiger Biopharmaceuticals (NASDAQ EIGR)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 263 (Vote Outperform)Underperform Votes: 176 (Vote Underperform)Total Votes: 439MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EIGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: What does RSI mean?